{"editorial":{"content_id":"797f5c04-ebf0-4d28-bf96-55783769a65f","slug":"farma-conde-ifood-glp-20261108-62cfc6","content_type":"news","title":"Farma Conde在iFood开卖GLP-1药物，预计月收入最高增40%","summary":"巴西连锁药房Farma Conde通过iFood销售GLP-1类似物药物，预计该渠道月收入可提升20%至40%。","body":"巴西连锁药房Farma Conde已开始在iFood平台销售GLP-1类似物药物，公司估计这类药品的销售可使该渠道月收入提升20%至40%。销售须遵循现行卫生要求，并出示和验证医生处方。\n\n据该公司多渠道经理朱利安·加齐（Julian Gazzi）介绍，这一合作旨在加速数字渠道增长，将品牌影响力与平台的覆盖范围相结合。按照应用公布的流程，客户在系统内填写数字处方数据，信息传送至门店，由负责药剂师分析并验证。加齐表示，该合作扩大了数字触达并便利消费者获取，同时不放弃对这些产品销售和调剂所需的必要管控。\n\n试点项目于9月启动，在圣保罗市10家门店提供注射笔；10月扩展至所有具备iFood销售资格的Farma Conde门店。加齐称，项目不仅需要技术开发，还需要联合研究、测试和假设验证，重点始终是保障消费者安全、运营可行性和合规。公司未透露开发成本如何在两家企业间分摊。此举属于扩大平台处方药组合的更广泛战略的一部分；加齐虽表示有意纳入其他品类，但未说明具体品类。\n\nFarma Conde 2025年iFood渠道销售额增长98%，今年预期增长80%。加齐表示，GLP-1销售是额外的增长机会，顺应巴西药品零售中快速增长的品类。\n\n今年3月，Farma Conde宣布与iFood达成战略合作，在最后一公里配送应用渠道独家运营，协议还允许双方联合开展宣传和贸易营销活动。该公司营销经理莱安德罗·瓦斯（Leandro Vaz）表示，平台上的曝光也将通过联合工作得到推动；双方还在与制药工业构建商业协议。\n\nFarma Conde创始人、药剂师克劳迪娅·孔德（Claudia Conde）表示，技术应服务于人，尤其是在健康领域，公司承诺在不妨碍安全、药学指导和负责任照护的前提下提供更多便利。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["企业动态","行业趋势","市场进入","br-health"],"content_level":"编辑整理","event_type":"公司动态","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-11-08T11:02:30.970Z","display_date":"2026-11-08","source_published_at":null,"source_url":"https://panoramafarmaceutico.com.br/farma-conde-projeta-ate-40-de-alta-com-glp-1-no-ifood/","source_name":"Panorama Farmacêutico","source_language":"pt","author_name":"编辑部","risk_level":"medium","risk_flags":["compliance_risk","legal_risk"],"opportunity_flags":["partnership_opportunity","market_entry_opportunity"],"trend_signals":["digital_pharmacy_expansion","prescription_drug_ecommerce_growth"]},"intelligence":{"intel_id":"920f3b88-0e2d-4dbf-95aa-e6cbed665ef1","version":1,"event_type":"平台接入","event_date":null,"main_entities":[{"name":"Farma Conde","role":"巴西连锁药房，GLP-1类似物药物的销售方","type":"company","country":"巴西","normalized_name":null},{"name":"iFood","role":"巴西配送与销售平台，提供药品销售渠道","type":"platform","country":"巴西","normalized_name":null},{"name":"GLP-1类似物药物","role":"通过iFood平台销售并需处方验证的药品品类","type":"product","country":"其他","normalized_name":null},{"name":"朱利安·加齐","role":"Farma Conde多渠道经理，介绍合作与合规流程","type":"person","country":"巴西","normalized_name":null},{"name":"圣保罗市","role":"试点项目启动城市","type":"location","country":"巴西","normalized_name":null}],"main_action":"Farma Conde通过iFood上线GLP-1类似物药物并凭处方销售，预计月收入增20%至40%。","key_numbers":[{"unit":"%","label":"该渠道月收入提升幅度","value":"20-40"},{"unit":"%","label":"2025年iFood渠道销售额增长","value":"98"},{"unit":"%","label":"今年iFood渠道销售额预期增长","value":"80"},{"unit":"家","label":"试点门店数量","value":"10"}],"facts":[{"verified":false,"statement":"Farma Conde已开始在iFood平台销售GLP-1类似物药物。","source_excerpt":null},{"verified":false,"statement":"该类药品销售须遵循现行卫生要求，并出示和验证医生处方。","source_excerpt":null},{"verified":false,"statement":"试点项目于9月启动，在圣保罗市10家门店提供注射笔。","source_excerpt":null},{"verified":false,"statement":"10月扩展至所有具备iFood销售资格的Farma Conde门店。","source_excerpt":null},{"verified":false,"statement":"Farma Conde 2025年iFood渠道销售额增长98%，今年预期增长80%。","source_excerpt":null},{"verified":false,"statement":"今年3月，Farma Conde宣布与iFood达成战略合作，在最后一公里配送应用渠道独家运营。","source_excerpt":null}],"assessments":[{"statement":"该合作是Farma Conde加速数字渠道增长并扩大平台处方药组合的举措。","confidence":"high","basis_fact_index":null},{"statement":"GLP-1类似物药物通过平台销售的关键在于处方验证与药学管控能否持续合规。","confidence":"medium","basis_fact_index":null},{"statement":"若销售表现符合公司预期，药品零售平台化可能成为巴西药房渠道增长点。","confidence":"medium","basis_fact_index":null}],"actions":[{"target":"both","priority":"high","description":"跟踪iFood平台上处方验证、药剂师审核与药品调剂流程是否符合卫生要求。"},{"target":"system","priority":"normal","description":"监测Farma Conde该渠道月收入增长是否达到20%至40%的预期区间。"},{"target":"user","priority":"normal","description":"关注Farma Conde与iFood是否扩展至其他处方药或药品品类。"}],"affected_audience":["使用iFood购药的消费者","GLP-1类似物药物患者","Farma Conde门店药剂师","Farma Conde","iFood"],"risk_flags":["compliance_risk","legal_risk"],"opportunity_flags":["partnership_opportunity","market_entry_opportunity"],"trend_signals":["digital_pharmacy_expansion","prescription_drug_ecommerce_growth"],"follow_up_needed":true,"follow_up_questions":["Farma Conde在iFood销售的GLP-1类似物具体包含哪些药品和品牌？","数字处方数据传送至门店后的药剂师审核与处方验证细节如何？","20%至40%月收入提升预期的测算依据和观察周期是什么？","该合作是否已获得所有必要的卫生监管许可或备案？","Farma Conde与iFood的开发成本分摊和商业协议细节如何？"],"related_topics":["GLP-1","iFood","处方药电商","巴西药房零售","数字医疗","药品合规"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-11-08T11:02:47.759Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/farma-conde-ifood-glp-20261108-62cfc6","api_url":"https://chinabrazilinsight.com/api/public/content/farma-conde-ifood-glp-20261108-62cfc6","markdown_url":"https://chinabrazilinsight.com/api/public/content/farma-conde-ifood-glp-20261108-62cfc6?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/farma-conde-ifood-glp-20261108-62cfc6?view=json","last_updated":"2026-11-08T11:02:48.142Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}